6IIX | pdb_00006iix

The crystal structure of acyltransferase mutant, orf11*-W163A, in complex with octanoyl-CoA


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.73 Å
  • R-Value Free: 
    0.212 (Depositor), 0.226 (DCC) 
  • R-Value Work: 
    0.190 (Depositor), 0.199 (DCC) 
  • R-Value Observed: 
    0.191 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 6IIX

Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history

Literature

Teicoplanin Reprogrammed with the N-Acyl-Glucosamine Pharmacophore at the Penultimate Residue of Aglycone Acquires Broad-Spectrum Antimicrobial Activities Effectively Killing Gram-Positive and -Negative Pathogens.

Huang, C.M.Lyu, S.Y.Lin, K.H.Chen, C.L.Chen, M.H.Shih, H.W.Hsu, N.S.Lo, I.W.Wang, Y.L.Li, Y.S.Wu, C.J.Li, T.L.

(2019) ACS Infect Dis 5: 430-442

  • DOI: https://doi.org/10.1021/acsinfecdis.8b00317
  • Primary Citation Related Structures: 
    6IIX, 6IIY

  • PubMed Abstract: 

    Lipoglycopeptide antibiotics, for example, teicoplanin (Tei) and A40926, are more potent than vancomycin against Gram-positive (Gram-(+)) drug-resistant pathogens, for example, methicillin-resistant Staphylococcus aureus (MRSA). To extend their therapeutic effectiveness on vancomycin-resistant S. aureus (VRSA), the biosynthetic pathway of the N-acyl glucosamine (Glc) pharmacophore at residue 4 (r4) of teicoplanin pseudoaglycone redirection to residue 6 (r6) was attempted. On the basis of crystal structures, two regioselective biocatalysts Orf2*T (a triple-mutation mutant S98A/V121A/F193Y) and Orf11*S (a single-mutation mutant W163A) were engineered, allowing them to act on GlcNAc at r6. New analogs thereby made show marked antimicrobial activity against MRSA and VRSA by 2-3 orders of magnitude better than teicoplanin and vancomycin. The lipid side chain of the Tei-analogs armed with a terminal mono- or diguanidino group extends the antimicrobial specificity from Gram-(+) to Gram-negative (Gram-(-)), comparable to that of kanamycin. In addition to low cytotoxicity and high safety, the Tei analogs exhibit new modes of action as a result of resensitization of VRSA and Acinetobacter baumannii. The redirection of the biosynthetic pathway for the N-acyl-Glc pharmacophore from r4 to r6 bodes well for large-scale production of selected r6,Tei congeners in an environmentally friendly synthetic biology approach.


  • Organizational Affiliation
    • Genomics Research Center , Academia Sinica , 128 Academia Road , Section 2, Nankang, Taipei 11529 , Taiwan.

Macromolecule Content 

  • Total Structure Weight: 40.18 kDa 
  • Atom Count: 3,041 
  • Modeled Residue Count: 323 
  • Deposited Residue Count: 345 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
acyltransferase345Actinoplanes teichomyceticusMutation(s): 2 
Gene Names: tcp24
UniProt
Find proteins for Q70AY4 (Actinoplanes teichomyceticus)
Explore Q70AY4 
Go to UniProtKB:  Q70AY4
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ70AY4
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.73 Å
  • R-Value Free:  0.212 (Depositor), 0.226 (DCC) 
  • R-Value Work:  0.190 (Depositor), 0.199 (DCC) 
  • R-Value Observed: 0.191 (Depositor) 
Space Group: P 65
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 132.536α = 90
b = 132.536β = 90
c = 48.598γ = 120
Software Package:
Software NamePurpose
REFMACrefinement
HKL-2000data reduction
HKL-2000data scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2019-10-09
    Type: Initial release
  • Version 1.1: 2020-10-21
    Changes: Database references
  • Version 1.2: 2023-11-22
    Changes: Data collection, Database references, Refinement description